Nermina Žiga Smajić

Nermina Žiga Smajić

Auto-generated profile, based on publicly available information

Nermina Žiga Smajić

University of Sarajevo, Sarajevo, Bosnia and Herzegovina

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2024 in Journal of Health Sciences
Verified
Journal Article
Open access
PDF file
EKEmina Koric
Emina Koric
IGIrma Gušić
Irma Gušić
KDKemal Durić
Kemal Durić
NŽNermina Žiga-Smajić
Nermina Žiga-Smajić
Amar OsmanovićAmar Osmanović
Amar Osmanović
HNHaris Nikšić
Haris Nikšić
Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint inflammation and destruction, leading to significant pain and disability. Adenosine deaminase (ADA) is identified as a biomarker for RA’s inflammatory process. This study aims to investigate the potential of flavonoids and phenolic acids to inhibit ADA activity (in silico) and evaluate their anti-inflammatory effects in a RA model (in vivo). Methods: The molecular docking study was conducted using YASARA Structure 19.12.14. software following the Auto Dock 4.2 protocol. A rat model with pristane-induced arthritis was used to test the anti-inflammatory effect of selected polyphenols. The consistency of the development of the rat model was evaluated through the following indicators artistic score, paw volume, and body weight. Quercetin was administered intragastrically at doses of 150 and 400 mg/kg over 15 days. The C-reactive protein (CRP) level in serum was measured with an automatic biochemical analyzer. Statistical analyses were performed using SPSS 29.0.2.0. Results: Molecular docking simulations showed flavonoids inhibited ADA activity with inhibition constants ranging from 0.012 mM to 0.190 mM. In the in vivo RA model, quercetin significantly reduced joint inflammation and serum CRP levels at a higher dose of 400 mg/kg. Conclusion: Quercetin shows promise as an anti-inflammatory agent for RA by targeting ADA, suggesting that flavonoid-rich plant extracts could enhance RA treatment.

31 July 2026 in Pharmacia
Verified
Journal Article
Open access
PDF file
ATAnela Hadžifejzović Trnka
Anela Hadžifejzović Trnka
NSNermina Žiga Smajić
Nermina Žiga Smajić
SŠSelma Škrbo
Selma Škrbo
Introduction : Older adults with type 2 diabetes mellitus (T2DM) frequently present with multiple comorbidities and complex therapeutic regimens, increasing the risk of potentially inappropriate medication (PIM) prescribing. This study aimed to assess the prevalence of PIM prescribing in geriatric patients with T2DM using the 2019 American Geriatrics Society Beers Criteria. Materials and methods : This observational, retrospective study included 400 geriatric patients (≥65 years) with T2DM. Data on prescribed medications were collected from medical records. Statistical analysis was performed using SPSS 13.0 and Microsoft Excel 2019 ( α = 0.05). Results : At least one PIM was identified in 60.8% of patients. Frequently prescribed PIMs included proton pump inhibitors (13.5%), diazepam (10.3%), and digoxin (6.5%) among medications to be avoided, and diuretics (59.5%) and acetylsalicylic acid (19.0%) among medications to be used with caution. Conclusion : Systematic application of the Beers Criteria may improve pharmacotherapy safety in this vulnerable population.

13 March 2026 in Pharmacia
Verified
Journal Article
Open access
PDF file
Naida Omerović ĆorovićNaida Omerović Ćorović
Naida Omerović Ćorović
TBTamer Bego
Tamer Bego
NSNermina Žiga Smajić
Nermina Žiga Smajić
HĆHalil Ćorović
Halil Ćorović
SŠSelma Škrbo
Selma Škrbo
Introduction : Drug–drug interactions (DDIs) influence treatment outcomes, particularly in complex diseases such as coronavirus disease 2019 (COVID-19). This study aimed to evaluate the impact of DDIs in COVID-19 patients. Materials and methods : A study was conducted on 200 patients with mild, moderate, or severe COVID-19 infections. Next, DDIs were classified into five risk categories (A–X). Results : Altogether, 1689 DDIs were identified (maximum of 64 per patient). Most interactions were category C (65.3%). Clinically significant DDIs (C–X) accounted for 73.6% of interactions. Positive correlations were found between the total number of DDIs and both the total number of drugs (very strong) and comorbidities/diagnoses (strong). Patients with severe COVID-19 infections had significantly more DDIs and drugs used. Polypharmacy was highly frequent (97.5%, average of 9.9 drugs per patient). Conclusion : Overall, COVID-19 patients often have clinically significant DDIs resulting from polypharmacy and comorbidities, especially in severe cases. Systematic DDI assessment is essential.